Küpfer A., Aeschlimann C., Wermuth B., Cerny T.Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet1994; 343: 763-64.
2.
David KA, Picus J.Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol2005; 28: 277-80.
3.
Sweiss KI, Beri R., Shord SSEncephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. Drug Saf2008; 31: 989-96.
4.
Patel PNMethylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother2006; 40: 299-303.
Buesa JM, García-Teijido P., Losa R., Fra J.Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res2003; 9: 4636-37.
7.
Desjardins P. , Butterworth RFRole of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke’s encephalopathy. Mol Neurobiol2005; 31: 17-25.
8.
Hamadani M., Awan F. . Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract2006; 12: 237-39.
